Weekly Update

Weekly Update: October 18 to October 22, 2021

New Studies with results available

6 new RCTs with results are available on our website: see here for vaccine et here for treatment

Dunkle L M, medRxiv, 2021	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Gupta S, Med J Armed Forces India, 2021	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection.
Hsieh SM, Lancet Respir. Med, 2021	Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Shu YJ, Chin Med J (Engl), 2021	Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Sridhar S, medrxiv, 2021	Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
Xia S, Lancet Infec Dis, 2021	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

8 new or updated vaccine observational studies with results are available on our website: see here

Charmet T, Lancet Reg Health Eur, 2021	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
Chemaitelly, N Eng J Med, 2021	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chung H, BMJ, 2021	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study
Giansante C, Acta Biomed, 2021	COVID-19 vaccine effectiveness among the staff of the Bologna Health Trust, Italy, December 2020-April 2021
Kim S, J Infect Dis, 2021	mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February - May 2021
Murugesan M, SSRN, 2021	Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India
Nasreen S, medRxiv,2021	Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada
Tenforde M, Clin Infect Dis, 2021	Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United State

Studies pending data extraction

23 new pharmacological and/or preventive RCTs:

Abd-Elsalam S, Am J Trop Med Hyg, 2021	Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial.
Arruda E A G, medrxiv, 2021	Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections
Azizi H, Int. Immunopharmacol., 2021	Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial
Babalola O, ResearchSquare, 2021	A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria
Barrett CD, Chest, 2021	STudy of Alteplase for Respiratory failure in SARS-Cov2 COVID-19 (STARS): A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized, Controlled Trial.
Bosteels C, ResearchSquare, 2021	Early treatment with inhaled GM-CSF improves oxygenation and anti-viral immunity in COVID-19 induced lung injury – a randomized clinical trial
Connors JM, JAMA, 2021	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Davoodi L, Int J Cardiol Heart Vasc, 2021	Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.
Dorward J, medrxiv, 2021	Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Ely W, medrxiv, 2021i	Baricitinib plus Standard of Care for Hospitalised Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized, Placebo-Controlled Trial.
Haghighi S, SSRN, 2021	The Effects of Thalidomide as an Adjuvant Treatment Besides of Dexamethasone and Remdesivir on Patients with Moderate COVID-19
Ibarra-Estrada MA, Crit Care Med, 2021	Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to Coronavirus Disease 2019: Results of a Single-Center Randomized Controlled Trial.
Kalil A, , Lancet Respir. Med, 2021	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Marcos M, Thromb Haemost, 2021	Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial.
Maskin LP, medrxiv, 2021	High- Versus Low-Dose Dexamethasone for the Treatment of COVID-19-related Acute Respiratory Distress Syndrome: A Multicenter and Randomized Open-label Clinical Trial
Nair PR, Respir Care, 2021	Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.
Page DB, Ann Am Thorac Soc, 2021	Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome: : A Randomized Pilot Study.
Panda PK, Clin Pharmacol, 2021	Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19.
Quinn TM, medrxiv, 2021	Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics
Ravishankar R, SSRN, 2021	Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Efficacy, Safety and Tolerability of Antiviral Drug Umifenovir vs Standard Care of Therapy in Non-Severe Covid-19 Patients
Spyropoulos A, JAMA Intern Med, 2021	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Tornero C, medrxiv, 2021	Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
Winthrop K, merdviv, 2021	Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial

6 new vaccine RCTs:

Angkasekwinai N, medrxiv, 2021	Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers
Chu L, medrxiv, 2021	Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Clemens S, ResearchSquare, 2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Fadlyana E, vaccine, 2021	A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
Perez-Rodriguez S, medrxiv, 2021	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity
Zhu F, Clin Infect Dis, 2021	Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial.

We have identified additional COVID-19 RCTs assessing:

1. long COVID
2. other interventions (dietary supplements or minerals and other technologies (e.g. cytokine adsorption)
3. other COVID vaccines.

These interventions were not prioritized but they might be included in the future. Details here